MEP7609A - Therapeutic agent for diabetes - Google Patents
Therapeutic agent for diabetesInfo
- Publication number
- MEP7609A MEP7609A MEP-76/09A MEP7609A MEP7609A ME P7609 A MEP7609 A ME P7609A ME P7609 A MEP7609 A ME P7609A ME P7609 A MEP7609 A ME P7609A
- Authority
- ME
- Montenegro
- Prior art keywords
- diabetes
- therapeutic agent
- symbol
- salt
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Ovaj pronalazak se odnosi na agnes za zašti tu pankreasa koji sadrži kombinaciju lijeka koji snižava glukoyu krvi, a ne sti muliše izlučivanje insulina, i jedinjenja predstavljenog formulom (II), gdje je svaki simbol defi nisan u opisu, ili njegove soli, u jedinjenja predstavljenog formulom (II), gdje je svaki sinbol defi nisan u opisu, ili njegove soli.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005379407 | 2005-12-28 | ||
JP2006061722 | 2006-03-07 | ||
PCT/JP2006/326141 WO2007074884A1 (ja) | 2005-12-28 | 2006-12-27 | 糖尿病治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP7609A true MEP7609A (en) | 2011-12-20 |
Family
ID=38218106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-76/09A MEP7609A (en) | 2005-12-28 | 2006-12-27 | Therapeutic agent for diabetes |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090042863A1 (bs) |
EP (1) | EP1970063A4 (bs) |
JP (1) | JP5094416B2 (bs) |
KR (1) | KR20080081354A (bs) |
AU (1) | AU2006330332B2 (bs) |
BR (1) | BRPI0620718A2 (bs) |
CA (1) | CA2635777A1 (bs) |
GE (1) | GEP20105033B (bs) |
IL (1) | IL192369A0 (bs) |
MA (1) | MA30176B1 (bs) |
ME (1) | MEP7609A (bs) |
MY (1) | MY152172A (bs) |
NO (1) | NO20083026L (bs) |
NZ (1) | NZ569661A (bs) |
RU (1) | RU2438671C2 (bs) |
WO (1) | WO2007074884A1 (bs) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0807453B8 (pt) * | 2007-02-01 | 2021-05-25 | Takeda Pharmaceuticals Co | preparação sólida |
MY159203A (en) * | 2007-07-19 | 2016-12-30 | Takeda Pharmaceuticals Co | Solid preparation comprising alogliptin and metformin hydrochloride |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
MX2010012245A (es) * | 2008-05-14 | 2011-04-11 | Sanwa Kagaku Kenkyusho Co | Medicina que consiste del uso concomitante o combinacion de un inhibidor de dpp-iv y otra medicina para diabeticos. |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
US20110190322A1 (en) | 2008-08-14 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
UY32126A (es) | 2008-09-25 | 2010-04-30 | Takeda Pharmaceutical | Composición farmacéutica sólida |
KR101054911B1 (ko) | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
EP2379522B1 (en) * | 2008-12-23 | 2018-02-28 | Sandoz AG | Crystalline form of alogliptin |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
AU2010212823B2 (en) | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
CN102753161A (zh) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗 |
CN102791701B (zh) | 2009-12-30 | 2014-02-12 | 深圳信立泰药业股份有限公司 | 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物 |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
EP3124041A1 (en) | 2010-06-24 | 2017-02-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
WO2013068875A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | 2-thiopyrimidinones |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
CR20170498A (es) | 2015-05-05 | 2018-01-26 | Pfizer | 2-tiopirimidinonas |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2263639A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
AU6944296A (en) | 1995-09-13 | 1997-04-01 | Takeda Chemical Industries Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
AU1285499A (en) | 1997-10-30 | 1999-05-24 | Merck & Co., Inc. | Somatostatin agonists |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
CA2386517A1 (en) | 1999-10-07 | 2001-04-12 | Takeda Chemical Industries, Ltd. | Amine derivatives |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
SI1228067T1 (en) | 1999-11-10 | 2005-02-28 | Takeda Chemical Industries, Ltd. | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
JP2003520226A (ja) * | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−iv阻害剤および抗糖尿病薬剤を含む組合せ物 |
ATE479429T1 (de) | 2000-04-28 | 2010-09-15 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US20050245571A1 (en) | 2001-10-19 | 2005-11-03 | Hidenori Abe | Amine derivative |
US7365069B2 (en) * | 2002-04-10 | 2008-04-29 | Bexel Pharmaceuticals Inc. | Pyrimidone derivatives |
US7470700B2 (en) | 2003-08-13 | 2008-12-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AU2004318013B8 (en) * | 2004-03-15 | 2011-10-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP4854511B2 (ja) * | 2004-08-26 | 2012-01-18 | 武田薬品工業株式会社 | 糖尿病治療剤 |
PE20070622A1 (es) * | 2005-09-14 | 2007-08-22 | Takeda Pharmaceutical | Administracion de inhibidores de dipeptidil peptidasa |
-
2006
- 2006-12-27 GE GEAP200610842A patent/GEP20105033B/en unknown
- 2006-12-27 US US12/087,122 patent/US20090042863A1/en not_active Abandoned
- 2006-12-27 BR BRPI0620718-9A patent/BRPI0620718A2/pt not_active IP Right Cessation
- 2006-12-27 EP EP06843523.9A patent/EP1970063A4/en not_active Withdrawn
- 2006-12-27 MY MYPI20082380 patent/MY152172A/en unknown
- 2006-12-27 AU AU2006330332A patent/AU2006330332B2/en not_active Ceased
- 2006-12-27 RU RU2008130878/15A patent/RU2438671C2/ru not_active IP Right Cessation
- 2006-12-27 ME MEP-76/09A patent/MEP7609A/xx unknown
- 2006-12-27 JP JP2007552016A patent/JP5094416B2/ja not_active Expired - Fee Related
- 2006-12-27 KR KR1020087018454A patent/KR20080081354A/ko active IP Right Grant
- 2006-12-27 NZ NZ569661A patent/NZ569661A/en not_active IP Right Cessation
- 2006-12-27 CA CA002635777A patent/CA2635777A1/en not_active Abandoned
- 2006-12-27 WO PCT/JP2006/326141 patent/WO2007074884A1/ja active Application Filing
-
2008
- 2008-06-22 IL IL192369A patent/IL192369A0/en unknown
- 2008-07-04 NO NO20083026A patent/NO20083026L/no not_active Application Discontinuation
- 2008-07-25 MA MA31144A patent/MA30176B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP5094416B2 (ja) | 2012-12-12 |
AU2006330332B2 (en) | 2012-03-08 |
EP1970063A4 (en) | 2014-05-21 |
NZ569661A (en) | 2011-06-30 |
AU2006330332A1 (en) | 2007-07-05 |
IL192369A0 (en) | 2011-08-01 |
EP1970063A1 (en) | 2008-09-17 |
RU2008130878A (ru) | 2010-02-10 |
US20090042863A1 (en) | 2009-02-12 |
MA30176B1 (fr) | 2009-01-02 |
KR20080081354A (ko) | 2008-09-09 |
JPWO2007074884A1 (ja) | 2009-06-04 |
GEP20105033B (en) | 2010-06-25 |
BRPI0620718A2 (pt) | 2011-11-22 |
WO2007074884A1 (ja) | 2007-07-05 |
NO20083026L (no) | 2008-09-16 |
RU2438671C2 (ru) | 2012-01-10 |
MY152172A (en) | 2014-08-15 |
CA2635777A1 (en) | 2007-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP7609A (en) | Therapeutic agent for diabetes | |
EA200700096A1 (ru) | Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии | |
BRPI0507198A (pt) | derivados de bisariluréia | |
EA201290078A1 (ru) | Гетероциклические соединения для ингибирования pask | |
TW200635878A (en) | Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use | |
MX2010001784A (es) | Activadores novedosos de la glucocinasa. | |
MX2009009416A (es) | Derivados de bencimidazol y sus metodos de uso. | |
MY149648A (en) | Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament | |
EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
MX2010002419A (es) | (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento. | |
DK1973541T3 (da) | Anvendelse af benzokondenserede heterocykliske sulfamidderivater til nedsættelse af lipid- og blodglucoseniveauer | |
DK1885187T3 (da) | Fremgangsmåde til behandling af lægemiddelresistent cancer | |
EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
UY28936A1 (es) | Grupo de compuestos benzoil-amino-heterociclilo y composiciones farmaceuticas que los comprenden, utiles para tratamiento de enfermedades mediadas por glucoquinasa (gq) | |
UY30659A1 (es) | Grupo de compuestos de benzoilamino heterociclico, composiciones farmacéuticas, porcesos para su preparacion y aplicaciones. | |
MX2010009736A (es) | Compuesto heterociclico. | |
GEP20115359B (en) | Fused cyclic compounds | |
NO20084919L (no) | Oksadiazolidindionforbindelse | |
NZ601483A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
BRPI0510411A (pt) | derivados de dióxido de oxazol-benzoisotiazol, processos para a sua fabricação e seu uso | |
TNSN06030A1 (en) | Substituted thiazole-benzoisothiazole dioxide derivavites, method for the production thereof and use of the same | |
EA200870089A1 (ru) | Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции | |
NO20090173L (no) | Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes | |
EA200800302A1 (ru) | Применение производных и аналогов тиазола при лечении рака | |
NO20063865L (no) | Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter |